Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will highlight efforts to expand access to genetic knowledge of prenatal and hereditary cancer at the 41^st Annual meeting of the National Society of Genetic Counselors (NSGC), November 16-19 in Nashville, Tennessee.

“In today’s patient-centric healthcare system, genetic counselors play a critical role in empowering patients and physicians with data-driven genetic information and personalized medical information to support critical healthcare decisions. said Paul J. Diaz, President and CEO of Myriad Genetics. “We are committed to increasing collaboration with the genetic counseling community to make genetic testing more accessible, affordable and easier to use for all patient populations.

On Saturday, November 19 at 12:30 p.m. CT, Myriad will host a CEU symposium titled ‘How inclusion, accessibility, innovation and collaboration are shaping the future of precision medicine,” presented by Nicole Lambert, Deputy CEO; Thomas Slavin, MD, chief medical officer; Dale Muzzey, Ph.D., Scientific Director; and Susan Manley, senior vice president of medical services. Myriad will also share a poster titled ‘Curation of Genome-Wide Pathogen Copy Number Variants in Noninvasive Prenatal Screening (NIPS)” by Sam Cox, Ph.D., Principal Investigator in Clinical Genomics. The data will highlight how technological improvements now enable the detection of copy number variants (CNVs) across the genome in NIPS.

Among the Myriad products featured in the company’s NSGC exhibit (#307) are:

• MyRisk™ with RiskScore^®, Myriad’s market-leading hereditary cancer screening test that offers the first polygenic breast cancer risk assessment for women of all backgrounds. RiskScore provides a personalized 5-year and lifetime risk of developing breast cancer for women eligible for MyRisk. JCO Precision Oncology recently published a study¹ which highlights the development and validation of RiskScore for women of all backgrounds. The study looked at data from more than 275,000 women of diverse ancestry to validate the use of ancestry-informative genetic markers. The results showed that the new method was more accurate for women of all backgrounds.

• Prequel^® with AMPLIFY technology, a non-invasive prenatal screening (NIPS) that helps determine if a pregnancy is at increased risk for common chromosomal abnormalities, regardless of ancestry or body mass index.

• Foresight^®prenatal carrier screening to detect couples at risk of transmitting serious hereditary diseases.

• Precise™ Oncology Solutions, a comprehensive suite of solutions offering simplified testing and reporting for germline testing, tumor profiling, and companion diagnostic options to guide cancer treatment decisions.

The story continues

Myriad live from the NSGC
Myriad will host a series of NSGC live streams available on the company’s social media channels – Facebook, LinkedIn and Twitter – including the following:

• Fireside chat with Myriad Genetics CEO Paul J. Diaz
  Friday, November 18: 12:15 p.m. to 12:30 p.m. CT
  Paul J. Diaz, President and CEO of Myriad Genetics, and Susan Manley, LCGC, Senior Vice President of Medical Services, discuss Myriad’s transformation and growth initiatives and its engagement with genetic counselors.

• Advancing Health Equity in Antenatal Care
  Friday, November 18: 1:00 p.m.-1:15 p.m. CT
  Kira Dineen, MS, LCGC, CG (ASCP) CM, Founder of the DNA Today Podcast and Prenatal Genetics Counselor at Maternal Fetal Care PC, and Thomas Slavin, MD, Chief Medical Officer, Myriad Genetics, explore technological advancements that improve the equity in prenatal care care.

• The inside scoop on the NSGC’s 41st Annual Conference
  Friday, November 18: 1:40-2:00 p.m. CT
  Melanie Hardy, MS, MS, CGC, Emory University and NSGC Annual Conference Committee Chair and Nicole Lambert, Chief Operating Officer, Myriad Genetics, review key national conference developments highlighting emphasis on advancing the profession of genetic counseling.

• Speak frankly of an NSGC newbie
  Friday, November 18: 3:30-3:45 p.m. CT
  Kamille Clever, MS, CGC, Cleveland Clinic and Shelly Cummings, CGC, Vice President of Oncology Medical Affairs, Myriad Genetics, discuss navigating the NSGC conference and share their first impressions.

• Precision medicine – now and after
  Friday, November 18: 4:00 p.m.-4:20 p.m. CST
  Dale Muzzey, Ph.D., Chief Scientific Officer of Myriad Genetics, and Katie Ziegler, Regional Medical Specialist, share their insights into new innovations and product advancements that are shaping the future of precision medicine.

• Empowering women to take control of their breast health
  Friday, November 18: 5:00 p.m.-5:15 p.m. CT
  Laura Crandon, President and Founder, Touch4Life and Gwen Turner, ESG, Diversity, Equity and Inclusion Manager, Myriad Genetics, discuss collaborative ways to help all women be active in breast health for life.

Special Events for Genetic Counselors
Myriad Genetics will be sponsoring the NSGC Welcome Reception for all genetic counselors attending the conference for the first time on Wednesday, November 16, 6:00-7:00 PM CT. Myriad will also host its 9^e Annual Genetic Counselor Appreciation Event and Fundraiser on Friday, November 18, 7:30-11:30 p.m. CT, supporting Touch4Life; Eva’s Butterfly Wishes/National Organization for Rare Disorders; and CONNECTUS Health.

^{_{1 Hughes et al. JCO Precision Oncology 2022 (https://ascopubs.org/doi/abs/10.1200/PO.22.00084)}}

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to promoting health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing a disease or its progression and guide treatment decisions in medical specialties where genetic information can significantly improve patient care and reduce healthcare costs. . Fast Company has named Myriad one of the World’s Most Innovative Companies for 2022. For more information, visit www.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, SneakPeek, Health.Illuminated., RiskScore , Prolaris, GeneSight and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s commitment to increase its collaboration with the genetic counseling community to make testing genetics more accessible, affordable and easier to use. for all patient populations. These “forward-looking statements” are based on management’s expectations regarding future events as of the date hereof and are subject to a number of known and unknown risks and uncertainties that could cause the results, conditions and actual events differ materially and adversely from those anticipated. These factors include the risks described in the company’s filings with the United States Securities and Exchange Commission, including the company’s annual report on Form 10-K filed on February 25, 2022, as well as any updates of these risk factors filed from time to time in the company’s quarterly reports on Form 10-Q or current reports on Form 8-K.